• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Molecular basis for universal HLA-A*0201-restricted CD8+ T-cell immunity against influenza viruses

tetano

Editor, Senior Moderator
Proc Natl Acad Sci U S A. 2016 Mar 31. pii: 201603106. [Epub ahead of print]
[h=1]Molecular basis for universal HLA-A*0201-restricted CD8+ T-cell immunity against influenza viruses.[/h] Valkenburg SA[SUP]1[/SUP], Josephs TM[SUP]2[/SUP], Clemens EB[SUP]1[/SUP], Grant EJ[SUP]1[/SUP], Nguyen TH[SUP]1[/SUP], Wang GC[SUP]3[/SUP], Price DA[SUP]4[/SUP], Miller A[SUP]5[/SUP], Tong SY[SUP]6[/SUP], Thomas PG[SUP]7[/SUP], Doherty PC[SUP]8[/SUP], Rossjohn J[SUP]9[/SUP], Gras S[SUP]10[/SUP], Kedzierska K[SUP]11[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] Memory CD8[SUP]+[/SUP]T lymphocytes (CTLs) specific for antigenic peptides derived from internal viral proteins confer broad protection against distinct strains of influenza A virus (IAV). However, immune efficacy can be undermined by the emergence of escape mutants. To determine how T-cell receptor (TCR) composition relates to IAV epitope variability, we used ex vivo peptide-HLA tetramer enrichment and single-cell multiplex analysis to compare TCRs targeted to the largely conserved HLA-A*0201-M1[SUB]58[/SUB]and the hypervariable HLA-B*3501-NP[SUB]418[/SUB]antigens. The TCRαβs for HLA-B*3501-NP[SUB]418[/SUB] [SUP]+[/SUP]CTLs varied among individuals and across IAV strains, indicating that a range of mutated peptides will prime different NP[SUB]418[/SUB]-specific CTL sets. Conversely, a dominant public TRAV27/TRBV19[SUP]+[/SUP]TCRαβ was selected in HLA-A*0201[SUP]+[/SUP]donors responding to M1[SUB]58[/SUB] This public TCR cross-recognized naturally occurring M1[SUB]58[/SUB]variants complexed with HLA-A*0201. Ternary structures showed that induced-fit molecular mimicry underpins TRAV27/TRBV19[SUP]+[/SUP]TCR specificity for the WT and mutant M1[SUB]58[/SUB]peptides, suggesting the possibility of universal CTL immunity in HLA-A*0201[SUP]+[/SUP]individuals. Combined with the high population frequency of HLA-A*0201, these data potentially explain the relative conservation of M1[SUB]58[/SUB] Moreover, our results suggest that vaccination strategies aimed at generating broad protection should incorporate variant peptides to elicit cross-reactive responses against other specificities, especially those that may be relatively infrequent among IAV-primed memory CTLs.


[h=4]KEYWORDS:[/h] T-cell receptor; human CD8+ T cells; influenza infection

PMID: 27036003 [PubMed - as supplied by publisher]
 
Back
Top Bottom